With a market capitalization (market cap) of $33.81B — a measure of how much the company is worth — DexCom, Inc. is the 435th most valuable company in Healthcare as of August 18, 2026. Shares trade at $89.60, up +0.95% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Visit websiteAs of August 18, 2026, DexCom, Inc. (DXCM) is worth $33.81B — this is its market capitalization, the total value of all its outstanding shares.
DexCom, Inc.’s market cap is $33.81B, which ranks it #435 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
DexCom, Inc. (DXCM) shares trade at $89.60, up 0.95% on the day, as of August 18, 2026.
DexCom, Inc. trades at a price-to-earnings (P/E) ratio of 41.9, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025